DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Mononine (Coagulation Factor IX Human) - Summary



Mononine, Coagulation Factor IX (Human), is a sterile, stable, lyophilized concentrate of Factor IX prepared from pooled human plasma and is intended for use in therapy of Factor IX deficiency, known as Hemophilia B or Christmas disease. Mononine is purified of extraneous plasma-derived proteins, including Factors II, VII and X, by use of immunoaffinity chromatography.

Mononine is indicated for the prevention and control of bleeding in Factor IX deficiency, also known as Hemophilia B or Christmas disease.

Mononine is not indicated in the treatment or prophylaxis of Hemophilia A patients with inhibitors to Factor VIII.

Mononine contains non-detectable levels of Factors II, VII and X (<0.0025 IU per Factor IX unit using standard coagulation assays) and is, therefore, not indicated for replacement therapy of these clotting factors.

Mononine is also not indicated in the treatment or reversal of coumarin-induced anticoagulation or in a hemorrhagic state caused by hepatitis-induced lack of production of liver dependent coagulation factors.

See all Mononine indications & dosage >>


Media Articles Related to Mononine (Coagulation Factor IX Human)

Low-cost blood test good predictor of increased bleeding risk in pediatric trauma patients
Source: Blood / Hematology News From Medical News Today [2015.09.30]
A team of researchers from the Trauma Program at Children's Hospital Los Angeles conclude that an admission hematocrit provides a reliable screening test for identifying pediatric patients who are at...

Make the Diagnosis: Episodic GI Bleeding
Source: MedPage Today Gastroenterology [2015.09.30]
(MedPage Today) -- Case Findings: A 39 year-old male patient with no significant medical history presents with a 2 year history of episodic gastrointestinal bleeding. The patient endorses both melena and hematochezia. The patient denies NSAID use, change in stool caliber, or abdominal pain. After negative gastroscopy and colonoscopy, capsule endoscopy was undertaken and revealed innumerable bluish 1-2 cm lesions along the walls of the small bowel. What is your diagnosis?

MRI improves diagnosis of microbleeding after brain injury in military personnel
Source: Radiology / Nuclear Medicine News From Medical News Today [2015.09.16]
Imaging patients soon after traumatic brain injury (TBI) occurs can lead to better (more accurate) detection of cerebral microhemorrhages, or microbleeding on the brain, according to a study of...

MRI Helps Detect Brain Bleeding Soon After Traumatic Brain Injury
Source: MedicineNet Brain Tumor Specialty [2015.09.16]
Title: MRI Helps Detect Brain Bleeding Soon After Traumatic Brain Injury
Category: Health News
Created: 9/15/2015 12:00:00 AM
Last Editorial Review: 9/16/2015 12:00:00 AM

Drug May Be Antidote to Bleeding Tied to Blood Thinner Pradaxa
Source: MedicineNet warfarin Specialty [2015.06.23]
Title: Drug May Be Antidote to Bleeding Tied to Blood Thinner Pradaxa
Category: Health News
Created: 6/22/2015 12:00:00 AM
Last Editorial Review: 6/23/2015 12:00:00 AM

more news >>

Published Studies Related to Mononine (Coagulation Factor IX Human)

A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. [2011.02]
Anticoagulants are the cornerstone of current acute coronary syndrome (ACS) therapy; however, anticoagulation regimens that aggressively reduce ischemic events are almost uniformly associated with more bleeding... The objectives of RADAR are (1) to determine the safety of a range of levels of RB006 reversal with RB007 after catheterization, (2) to confirm whether a dose of 1 mg/kg RB006 results in near-complete inhibition of factor IXa in patients with ACS, and (3) to assess the efficacy of RB006 as an anticoagulant in patients with ACS undergoing percutaneous coronary intervention.

First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. [2010.08.10]
CONCLUSIONS: This study demonstrates the clinical translation of a novel platform of anticoagulation targeting factor IXa and its active reversal to percutaneous coronary intervention and provides the basis for further investigation. CLINICAL TRIAL REGISTRATION:URL: http://www.clinicaltrials.gov. Unique identifier: NCT00715455.

Coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin and risk of coronary heart disease. [2010.04.30]
AIM: To examine whether plasma levels of coagulation factors II, V, IX, X, XI, and XII, plasminogen, and alpha-2 antiplasmin are associated with coronary heart disease (CHD) in a prospective case-cohort study... CONCLUSIONS: Positive associations of factors IX and XI, and alpha-2 antiplasmin with incident CHD were not strong and accounted for by classical coronary risk factors.

Effects of L-Carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients. [2010]
BACKGROUND: Hypercoagulability is an important risk factor for thrombosis and its complications in hemodialysis patients. This study was designed to investigate the effects of l-carnitine supplement on plasma coagulation and anticoagulation factors in hemodialysis patients... CONCLUSION: l-Carnitine supplement reduces serum CRP, a marker of systemic inflammation, and plasma fibrinogen, an inflammation-related coagulation factor, in hemodialysis patients. Therefore, l-carnitine may play an effective role in preventing cardiovascular diseases in these patients.

Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology. [2009.10.01]
Higher levels of procoagulant factors and factor XII deficiency may be risk factors for first venous thromboembolism (VTE). We studied associations of coagulation factors IX through XIII with risk of future VTE in 2 general population samples... Among these procoagulant factors, only elevated factor XI was a risk factor for VTE.

more studies >>

Page last updated: 2015-09-30

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2015